Rhino-Conjunctivitis - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhino-Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Rhino-Conjunctivitis (Ophthalmology) pipeline landscape.

Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 3, 5, 8, 3 and 1 respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Rhino-Conjunctivitis Overview 8
Therapeutics Development 9
Pipeline Products for Rhino-Conjunctivitis - Overview 9
Rhino-Conjunctivitis - Therapeutics under Development by Companies 10
Rhino-Conjunctivitis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Rhino-Conjunctivitis - Products under Development by Companies 14
Rhino-Conjunctivitis - Companies Involved in Therapeutics Development 15
ALK-Abello A/S 15
Allergy Therapeutics Plc 16
ASIT Biotech SA 17
Astellas Pharma Inc 18
Bial - Portela & Ca SA 19
Circassia Pharmaceuticals Plc 20
Griffin Discoveries BV 21
HAL Allergy BV 22
Laboratorios LETI SL 23
Oxagen Ltd 24
Roxall Medizin GmbH 25
Stallergenes Greer plc 26
Rhino-Conjunctivitis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Allergen for Allergic Rhino-Conjunctivitis - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Allergovac - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ASP-4070 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
clustoid wiesenlieschgras - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
gp-ASIT - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
hdm-ASIT - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
OC-2417 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Pollinex Quattro Grass - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Timapiprant - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Rhino-Conjunctivitis - Dormant Projects 70
Rhino-Conjunctivitis - Discontinued Products 72
Rhino-Conjunctivitis - Product Development Milestones 73
Featured News & Press Releases 73
Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study 73
Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 74
May 18, 2014: BioTech Tools will be present at the EAACI congress 75
Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 76
Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 77
Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 78
Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 78
Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables

Number of Products under Development for Rhino-Conjunctivitis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2016 15
Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H2 2016 16
Rhino-Conjunctivitis - Pipeline by ASIT Biotech SA, H2 2016 17
Rhino-Conjunctivitis - Pipeline by Astellas Pharma Inc, H2 2016 18
Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca SA, H2 2016 19
Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 20
Rhino-Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2016 21
Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2016 22
Rhino-Conjunctivitis - Pipeline by Laboratorios LETI SL, H2 2016 23
Rhino-Conjunctivitis - Pipeline by Oxagen Ltd, H2 2016 24
Rhino-Conjunctivitis - Pipeline by Roxall Medizin GmbH, H2 2016 25
Rhino-Conjunctivitis - Pipeline by Stallergenes Greer plc, H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Assessment by Combination Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Rhino-Conjunctivitis - Dormant Projects, H2 2016 70
Rhino-Conjunctivitis - Dormant Projects (Contd..1), H2 2016 71
Rhino-Conjunctivitis - Discontinued Products, H2 2016 72